Researchers Identify Target for Therapeutic Drugs to Fight Adult Brain Cancer
News Jan 16, 2006
A research team at UT Southwestern Medical Center has discovered a cell-signaling mechanism instrumental in the most common brain cancer in adults.
The study, published in an issue of the journal Cancer Research, opens an avenue to develop therapeutic drugs to target the epidermal growth factor receptor genes that play a major role in the development of deadly brain tumors, researchers said.
The median survival of patients with glioblastoma multiforme (GBM), a cancer of the supportive tissue of the brain, currently is about one year after diagnosis with the best treatments available, said Dr. Amyn Habib, assistant professor of neurology at UT Southwestern and the study’s senior author.
Researchers have known for years that tumor cells proliferate out of control by a mechanism characterized by an abnormally high number of copies of the epidermal growth factor receptor gene (EGFR).
This overexpression of EGFR, Dr. Habib said, is a striking feature of glioblastoma multiforme, present in 40 percent to 50 percent of tumors and results in an uncontrolled multiplication of both normal EGFR and a mutant form called EGFRvIII.
While studying human brain tumor tissue and human brain tumor cells from cell lines grown in the laboratory, Dr. Habib and his colleagues discovered that EGFRvIII generates a unique pattern of signaling (distinct from normal EGFR) that causes brain cancer cells in GBM to grow and multiply unchecked.
"The better we understand the signaling mechanisms of the normal and the mutant EGFR, the better we can manipulate or control them," Dr. Habib said.
"Our findings suggest that you have to target both the mutant and the normal EGFR based on the mechanism we described."
Dr. Habib said he hoped the findings gained from the new study could eventually lead to therapeutic drugs that destroy brain cancer cells and spare healthy cells.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.